KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Non-Current Deffered Revenue (2018 - 2025)

Historic Non-Current Deffered Revenue for Aurinia Pharmaceuticals (AUPH) over the last 4 years, with Q3 2025 value amounting to $12.2 million.

  • Aurinia Pharmaceuticals' Non-Current Deffered Revenue changed N/A to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Non-Current Deffered Revenue of $12.2 million as of Q3 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Non-Current Deffered Revenue peaked at $12.4 million during Q1 2025, and registered a low of $1.7 million during Q4 2024.